FindTrial
Sign In

A clinical study to determine the cognitive impairment in persons with drug resistant epilepsy on Anti Seizure Medications.

Cognitive impairment in persons with drug resistant epilepsy and correlation with homocysteine, pyridoxine, folic acid, cyanocobalamine and BDNF levels. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/076089
Enrollment
135
Registered
2024-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G409- Epilepsy, unspecified

Interventions

Control Intervention1: NIL: NIL

Sponsors

AIIMS, New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Persons with Drug Resistant Epilepsy diagnosed as per ILAE criteria 2. Subjects willing to participate and able to provide written informed consent. 3. Subjects with basic understanding of Hindi or English.

Exclusion criteria

Exclusion criteria: 1. Participants who are unwilling to participate and do not provide written informed consent. 2. Alcohol consumption. 3. Pregnant and lactating women. 4. History of other chronic communicable/ noncommunicable, medical illness.

Design outcomes

Primary

MeasureTime frame
Neurocognitive assessment using Montreal cognitive assessment (MoCA)scale, Addenbrooke’s Cognitive Examination-III (ACE-III) Scale, Mini-Mental State Examination (MMSE) Scale and MINI cognition scale. Serum biomarkers for BDNF, homocysteine, pyridoxine, folic acid and cyanocobalamine.Timepoint: At baseline—

Secondary

MeasureTime frame
To assess domain wise cognitive impairmentTimepoint: During statistical analysis—

Countries

India

Contacts

Public ContactDr Jatinder Katyal

All India Institute of Medical Sciences New Delhi

jatinderkatyal.aiims@gmail.com01126593282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026